(Q46253513)

English

Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

1 reference

based on heuristic

inferred from title

author name string

S Roy

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

D Hemsell

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

S Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

D Godwin

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

M Pearlman

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

D Luke

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

language of work or name

0 references

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

The American Journal of Surgery

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

176

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

6A Suppl

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

62S-66S

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Comparative effectiveness and safety of cefotetan and cefoxitin as prophylactic agents in patients undergoing abdominal or vaginal hysterectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vitro activity of the new fluoroquinolone CP-99,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Penetration of trovafloxacin into gynecologic tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

The chemistry and biological profile of trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Oral bioavailability of trovafloxacin with and without food in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Surgical infections: prevention and treatment--1965 to 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Prevention of major infection after elective abdominal hysterectomy: Individual determination required

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900222-0

7 January 2021

Identifiers

10.1016/S0002-9610(98)00222-0

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/9935259

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46253513&oldid=2102251888"